Navigation Links
Fewer adverse cardiac events at one year
Date:10/23/2007

WASHINGTON, DC OCTOBER 22, 2007 Late breaking results from the SPIRIT III trial, presented at TCT 2007, the annual scientific symposium of the Cardiovascular Research Foundation, show that after 12 months, there were significantly fewer major adverse cardiac events (MACE) such as heart attacks, deaths from cardiac causes or repeat procedures (angioplasty or surgery) to clear the original vessel blockage after using a Xience V everolimus-eluting coronary stent than a Taxus paclitaxel-eluting stent.

The rate of the primary endpoint, in-segment late loss (a measure of how much the artery re-narrows following stenting) was also reduced by 50% with the Xience V stent compared to Taxus. There were no significant differences in other secondary endpoints between the two stent types, including target vessel failure (a combination of repeat procedures anywhere in the involved blood vessel and adverse cardiac events), as well as stent thrombosis (dangerous blood clots that can form within the stent).

Both the primary endpoint of the trial and the major secondary endpoint were met, said Gregg W. Stone, MD, Chairman, Cardiovascular Research Foundation and Professor of Medicine, Columbia University Medical Center. Moreover, the reduction in major adverse cardiac events with the Xience V stent compared to the Taxus stent is an important finding that signifies improved long-term outcomes for patients with heart disease. Given this positive finding, which has never before been seen in a pivotal drug-eluting stent vs. stent trial, coupled with the ease of use of Xience, will result in this device becoming a favored drug-eluting stent for clinicians treating coronary disease.

Further studies are required to determine whether there are meaningful differences between the two stent types in low frequency safety events, and in important subgroups, Stone added.

SPIRIT III 12-Month Results

Everolimus-Eluting Stent Paclitaxel-Eluting Stent
Target Vessel Failure 8.3 percent 10.8 percent
MACE 5.8 percent 9.9 percent
Cardiac Death .8 percent .9 percent
MI 2.6 percent 3.7 percent
Ischemia-Driven TLR 3.3 percent 5.6 percent

The SPIRIT III trial was designed as a prospective, randomized, active-controlled, single blind, multi-center clinical trial, which enrolled 1,002 patients (65 different U.S. sites) with coronary artery disease.


'/>"/>

Contact: Irma Damhuis
idamhuis@crf.org
917-558-5180
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. Chemotherapy Pill Has Fewer Side Effects Than IV
2. Fewer teeth & Increased Ischemic Stroke risk
3. Heart Patients More At Risk Get Fewer Medicines
4. Fewer People Die Due To Cancer
5. Fewer Breast Cancer Patients to Get Chemo
6. Fewer Blacks Undergo Lung Cancer Surgery
7. Thailand had Fewer AIDS-Related Deaths, New HIV Cases In 2005
8. Fewer Neurons in Amygdala of Autistic Males
9. Women With Fewer Periods Have Low Risk Of Gynecological Cancer
10. Fewer Doctors Treating For Free
11. Fruits & Vegetables Makes You Look Younger With Fewer Wrinkles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... (PRWEB) , ... September 22, 2017 , ... MEDIA OPPORTUNITY: ... its rally to interview citizens on why they are rallying against Mayo Clinic. Specifically, ... to this effort against Dr. Noseworthy’s (CEO) decision to close the Albert Lea hospital. ...
(Date:9/22/2017)... York (PRWEB) , ... September 22, 2017 , ... ... and assembles Passive House buildings, and Richard Pedranti Architect (RPA), a ... House from the strategic partner’s Solsken Line of Model Homes . Independently, ...
(Date:9/22/2017)... ... September 22, 2017 , ... Happy Living’s mission - to improve the health ... into the entertaining and delicious worlds of theatre and wines. , After watching ... him to turn his play into a book. The Greener The Grass ( https://www.happyliving.com/books/the-greener-the-grass ...
(Date:9/22/2017)... Texas (PRWEB) , ... September 22, 2017 , ... ... network of independent freestanding emergency rooms is celebrating the one year anniversary of ... of our facility opening,” said Dr. Otinwa, Facility Medical Director of First Choice ...
(Date:9/22/2017)... ... September 22, 2017 , ... “Letters From Home”: ... even the lost, have value to God. “Letters From Home” is the creation of ... member of the President’s Cabinet of Jerry Savelle Ministries International, who has traveled and ...
Breaking Medicine News(10 mins):
(Date:9/5/2017)... 5, 2017 Sapheneia and Scannerside received FDA ... DoseCheck is a third-party Vendor neutral CT product that ... allows compliance with current MITA standards. ... DoseCheck solution is specifically designed to provide CT operators, ... radiation doses over a predefined threshold. Scannerside Dose Check ...
(Date:9/5/2017)... WAYNE, N.J. , Sept. 5, 2017 /PRNewswire/ ... technology, has created a vibrant charitable donation program ... funds and support congenital heart defect research by ... healthcare providers and the general public are encouraged ... and submit the completed artwork to the ...
(Date:9/5/2017)... -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ... focused on the development of oral drug delivery systems, ... with the U.S. Food and Drug Administration (FDA) regarding ... At the meeting, the FDA ... of ORMD-0801, would be a Biologics License Application (BLA).  ...
Breaking Medicine Technology: